Applications including "Pharmacopoeia"

LT199 - Analysis of voglibose tablets in accordance with the 18th revised Japanese Pharmacopoeia -

LC Technical Note Inertsil NH2
LT195 - Eighteenth revision Japanese Pharmacopoeia analysis of tranexamic acid -2.00 Condition change within the range specified in the general chromatography- -

LC Technical Note InertSustain AQ-C18
GT146 - Japanese Pharmacopoeia, 18th Edition Analysis of Saccharin Sodium Hydrate - 2.00 Change of Conditions Specified within General Theory of Chromatography -

GC Technical Note
GT145 - Japanese Pharmacopoeia, 18th Edition Analysis of Macrogol 400 - 2.00 Change of Conditions Specified within General Theory of Chromatography -

GC Technical Note
LB263 - Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil C8-3
LB206 - Analysis of Paroxetine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil TMS
LB161 - Analysis of Clopidogrel sulfate (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia, Clopidogrel sulfate Tablets) -

LC InertSearch InertSustain C18
LB099 - Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB094 - Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB085 - Analysis of Olmesartan medoxomil (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-2
GA271 - Analysis of Polysorbate80(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 5
GA270 - Analysis of Polysorbate80(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap Pure-WAX
GA113 - Residual solvents in pharmaceuticals -

GC InertSearch InertCap Pure-WAX
GA029 - Organic solvents -

GC InertSearch InertCap WAX
GA397 - Analysis of Nitromethane(Under the Condition of draft for USP, Tromethamine Hydrochloride, Limit of Nitromethane) -

GC InertSearch InertCap 624MS
LC110 - Analysis of Quinic acid, Malic acid, Citric acid, Shikimic acid (Under the Condition of draft for USP, Aronia melanocarpa Fruit Aqueous Dry Extract, IDENTIFICATION C.HPLC PROFILE AND RATIO OF ORGANIC ACIDS) -

LC InertSearch InertSustain AQ-C18
LC109 - Analysis of Prazosin hydrochloride (Under the Condition of draft for USP, Prazosin Hydrochloride Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustainC18
LC108 - Analysis of Formoterol fumarate (Under the Condition of draft for USP, Formoterol Fumarate Inhalation Solution, Assay) -

LC InertSearch InertCore C8
LC105 - Analysis of Cefalexin (Under the Condition of Japanese Pharmacopoeia 18th, Cefalexin,Purity(3) Related substances ) -

LC InertSearch InertSustainSwift C18
LC100 - Analysis of Omeprazole(Under the Condition of USP41-NF36, Omeprazole Delayed-Release Capsules, ASSAY) -

LC InertSearch InertSustain C8
LL043 - Analysis of Azithromycin (Based on the Condition of USP-NF 2025 Issue 2 Mar, Azithromycin Tablets, ORGANIC IMPURITIES) -

LC InertSearch Inertsil Hybrid-C18
LC099 - Analysis of Ascorbic acid (Under the Condition of draft for USP, Water-Soluble Vitamins Chewable Gels, Ascorbic acid, Method 1) -

LC InertSearch InertSustain C8
LC098 - Analysis of Tramadol Hydrochloride (Under the Condition of draft for USP, Tramadol Hydrochloride Tablets, ASSAY) -

LC InertSearch InertSustain C8
LC096 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ORGANIC IMPURITIES) -

LC InertSearch InertSustainSwift C18
LC095 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ASSAY) -

LC InertSearch InertSustainSwift C18
LC072 - Analysis of Vitamin K１ (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PHYTONADIONE) -

LC InertSearch InertSustain C18
LC070 - Analysis of Vitamin A (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin A,Method 1) -

LC InertSearch InertSustain NH2
LC068 - Analysis of Gliclazide (Under the Condition of the draft for Japanese Pharmacopoeia, Gliclazide Tablets, ASSAY) -

LC InertSearch Inertsil WP300 C18
LC067 - Analysis of Rebamipide (Under the Condition of the Japanese Pharmacopoeia 18th, Rebamipide, Purity (4) Related Substances -

LC InertSearch Inertsil ODS-3
LC066 - Analysis of Cidofovir (Under the Condition of USP43-NF38, Cidofovir, ASSAY) -

LC InertSearch Inertsil Hybrid-C18
LC065 - Analysis of Vitamin E (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 1) -

LC InertSearch InertSustain C18
LC064 - Analysis of Pioglitazone Hydrochloride and Glimepiride (Under the Condition of the Japanese Pharmacopoeia 18th, Pioglitazone Hydrochloride and Glimepiride Tablets, ASSAY(2)Glimepiride) -

LC InertSearch InertSustainSwift C18
LC063 - Analysis of Pioglitazone Hydrochloride and Glimepiride (Under the Condition of the Japanese Pharmacopoeia 18th, Pioglitazone Hydrochloride and Glimepiride Tablets, ASSAY(1)Pioglitazone Hydrochloride) -

LC InertSearch InertSustainSwift C18
LC062 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin, DISSOLUTION) -

LC InertSearch Inertsil Hybrid-C18
LC061 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin,ASSAY) -

LC InertSearch Inertsil Hybrid-C18
LC060 - Analysis of Aspirin (Under the Condition of the draft for the Japanese Pharmacopoeia 19th, Aspirin Delayed-release Tablets, ASSAY) -

LC InertSearch InertSustain C18
LC059 - Analysis of 1-Fluoro-2,4-dinitrophenyl-5-L-alaninamide (Under the Condition of the draft for the Japanese Pharmacopoeia 19th, Pregabalin, 1-Fluoro-2,4-dinitrophenyl-5-L-alaninamide, Assay) -

LC InertSearch InertSustain AQ-C18
LC058 - Analysis of Folic acid (Under the Condition of USP NF 2022 ISSUE 3, <411>FOLIC ACID ASSAY,_Procedure 1) -

LC InertSearch InertSustainSwift C18
LC057 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Tablets, ASSAY) -

LC InertSearch InertSustain C18
LC056 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol, ASSAY) -

LC InertSearch InertSustain C18
LC055 - Analysis of Dobutamine (Under the Condition of the USPNF 2023 Issue 2, Dobutamine Hydrochloride, ASSAY) -

LC InertSearch Inertsil WP300 C18
LC054 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Injection, ASSAY) -

LC InertSearch InertSustain C18
LC053 - Analysis of Folic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,FOLIC ACID_Method 2) -

LC InertSearch InertSustain C8
LC052 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 2) -

LC InertSearch InertSustain C8
LC051 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 1) -

LC InertSearch InertSustain AQ-C18
LC050 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 3) -

LC InertSearch Inertsil WP300 C18
LC049 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 2) -

LC InertSearch InertSustain C18
LC042 - Analysis of Nicotinic acid,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method3 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method3) -

LC InertSearch InertSustain C8
LC041 - Analysis of Nicotinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method1 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method1) -

LC InertSearch InertSustain C18
LC040 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, IMPURITIES, Limit of Free 4-Aminophenol) -

LC InertSearch InertSustainSwift C8
LC039 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, ASSAY) -

LC InertSearch InertSustainSwift C8
LC037 - Analysis of Amlodipine Besilate (Under the Condition of the Japanese Pharmacopoeia 18th, Amlodipine Besilate, Purity(2) Related Substances) -

LC InertSearch InertSustain C18
LC036 - Analysis of Zonisamide (Under the Condition of USP41-NF36, Zonisamide Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustain C18
LC035 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide Capsules, ASSAY) -

LC InertSearch InertSustain C18
LC034 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide, ASSAY) -

LC InertSearch InertSustain C18
LC033 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Oil- and Water-Soluble Vitamins Minerals Tablets,BIOTIN_Method 3) -

LC InertSearch InertSustain C18
LC032 - Analysis of D‐Biotin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,BIOTIN_Method 1) -

LC InertSearch InertSustain C8
LC031 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Biotin) -

LC InertSearch InertSustain C8
LC029 - Analysis of Riboflavin (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,RIBOFLAVIN_Method 2) -

LC InertSearch InertSustain C18
LC028 - Analysis of Pyridoxine hydrochloride (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PYRIDOXINE HYDROCHLORIDE_Method 2) -

LC InertSearch InertSustain C18
LC027 - Analysis of Nicotinamide (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,NIACINAMIDE_Method 2) -

LC InertSearch InertSustain C18
LC026 - Analysis of Nicotinic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin_Method 2) -

LC InertSearch InertSustain C18
LC023 - Analysis of Lansoprazole (Under the Condition of the USP41-NF36, Lansoprazole Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustain C18
LC022 - Analysis of Ursodeoxycholic acid (Under the Condition of the Japanese Pharmacopoeia 18th, Ursodeoxycholic acid Tablets, Ursodeoxycholic acid Granules) -

LC InertSearch InertSustain C18
LC021 - Analysis of Cyanocobalamin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Cyanocobalamin_Method1) -

LC InertSearch Inertsil ODS-HL
LC017 - Analysis of Itraconazole (Under the Condition of Japanese Pharmacopoeia 18th, Itraconazole, Purity(2) Related substances) -

LC InertSearch InertSustain C18
LC016 - Analysis of Itraconazole (Under the Condition of USP-NF 2021 Issue 2, Itraconazole Capsules, ASSAY) -

LC InertSearch InertSustain C18
LC014 - Analysis of Itraconazole (Under the Condition of USP43-NF38, Itraconazole, ASSAY) -

LC InertSearch InertSustainSwift C18
LC012 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

LC InertSearch Inertsil NH2
LC009 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC InertSearch Inertsil ODS-3
LC008 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC InertSearch InertSustain C18
LB991 - Analysis of Progestrone and Methyltestrone -

LC InertSearch Inertsil WP300 C18
LB985 - Analysis of Sumatriptan -

LC InertSearch Inertsil ODS-3
LB984 - Analysis of Sumatriptan -

LC InertSearch InertSustain AQ-C18
LB982 - Analysis of Ofloxacin -

LC InertSearch InertSustain C18
LB981 - Analysis of Ofloxacin -

LC InertSearch Inertsil WP300 C18
LB980 - Analysis of Desloratadine -

LC InertSearch InertSustain AQ-C18
LB978 - Analysis of Hydrochlorothiazide -

LC InertSearch InertSustain AQ-C18
LB961 - Analysis of Lidocaine -

LC InertSearch Insertsil WP300 C18
LB960 - Analysis of Lidocaine -

LC InertSearch Insertsil WP300 C18
GA381 - Analysis of Residual solvents in pharmaceuticals (Class 3) -

GC InertSearch InertCap Pure-WAX
GA380 - Analysis of Residual solvents in pharmaceuticals (Class 3) -

GC InertSearch InertCap 624MS
GA375 - Analysis of Residual solvents in pharmaceuticals (Class 2E) -

GC InertSearch InertCap Pure-WAX
GA374 - Analysis of Residual solvents in pharmaceuticals (Class 2E) -

GC InertSearch InertCap 624MS
GA373 - Analysis of Residual solvents in pharmaceuticals (Class 2E) -

GC InertSearch InertCap 624MS
GA372 - Analysis of Residual solvents in pharmaceuticals (Class 2D) -

GC InertSearch InertCap Pure-WAX
GA371 - Analysis of Residual solvents in pharmaceuticals (Class 2D) -

GC InertSearch InertCap 624MS
GA370 - Analysis of Residual solvents in pharmaceuticals (Class 2D) -

GC InertSearch InertCap 624MS
LB953 - Analysis of Pregabalin (Under the Condition of the draft for the Japanese Pharmacopoeia, Pregabalin Orally Disintegrating Tablets, Pregabalin Capsules) -

LC InertSearch InertSustain Cyano
LB952 - Analysis of Pregabalin (Under the Condition of the draft for the Japanese Pharmacopoeia, Pregabalin Orally Disintegrating Tablets) -

LC InertSearch InertSustain C18
LB951 - Analysis of Pregabalin (Under the Condition of the draft for the Japanese Pharmacopoeia, Pregabalin Capsules) -

LC InertSearch InertSustain C18
LB950 - Analysis of Pregabalin (Under the Condition of the draft for the Japanese Pharmacopoeia, Pregabalin) -

LC InertSearch InertSustain C18
LB948 - Analysis of Omeprazole -

LC InertSearch Inertsil C8-3
LB937 - Analysis of Febuxostat -

LC InertSearch Inertsil ODS-4
LB936 - Analysis of Febuxostat -

LC InertSearch InertSustain C30
LB935 - Analysis of Febuxostat -

LC InertSearch InertSustain AQ-C18
GA367 - Analysis of Propylene glycol -

GC InertSearch InertCap Pure-WAX
LB933 - Analysis of Diclofenac sodium -

LC InertSearch Inertsil WP300 C18
LB930 - Analysis of Blonanserin -

LC InertSearch InertSustain C18
LB929 - Analysis of Blonanserin -

LC InertSearch InertSustain C18
LB928 - Analysis of Blonanserin -

LC InertSearch InertSustain C18
LB927 - Analysis of Blonanserin -

LC InertSearch InertSustain C18
LB926 - Analysis of Piperacillin Sodium -

LC InertSearch Inertsil WP300 C18
LB882 - Analysis of Paracetamol and Mefenamic acid -

LC InertSearch InertSustain C18
LB881 - Analysis of Paracetamol and Mefenamic acid -

LC InertSearch Inertsil ODS-3
LB880 - Analysis of Paracetamol and Mefenamic acid -

LC InertSearch InertSustain C18
LB879 - Analysis of Paracetamol and Mefenamic acid -

LC InertSearch Inertsil ODS-3
LB878 - Analysis of Mefenamic acid -

LC InertSearch InertSustain C18
LB877 - Analysis of Mefenamic acid -

LC InertSearch Inertsil ODS-3
LB849 - Analysis of Tolvaptan (Under the Condition of the draft for the Japanese Pharmacopoeia 18th SupplementII) -

LC InertSearch Inertsil ODS-4
LB848 - Analysis of Tolvaptan (Under the Condition of the draft for the Japanese Pharmacopoeia 18th SupplementII) -

LC InertSearch Inertsil ODS-4
LB806 - Analysis of Ampicillin and Sulbactam (Under the Condition of the Japanese Pharmacopoeia 18th , Ampicillin Sodium and Sulbactam Sodium for Injection) -

LC InertSearch Inertsil ODS-HL
LB761 - Analysis of Doripenem (Under the Condition of the Japanese Pharmacopoeia 18th, Doripenem Hydrate) -

LC InertSearch Inertsil ODS-4
LB760 - Analysis of Doripenem (Under the Condition of the Japanese Pharmacopoeia 18th, Doripenem Hydrate) -

LC InertSearch InertSustain C18
LB759 - Analysis of Doripenem (Under the Condition of the Japanese Pharmacopoeia 18th, Doripenem Hydrate) -

LC InertSearch InertSustain AX-C18
LB758 - Analysis of Doripenem (Under the Condition of the Japanese Pharmacopoeia 18th, Doripenem Hydrate) -

LC InertSearch InertSustain C18
LB757 - Analysis of Fenofibrate (Under the Condition of the Japanese Pharmacopoeia 18th) -

LC InertSearch Inertsil ODS-4
LB756 - Analysis of Fenofibrate (Under the Condition of the Japanese Pharmacopoeia 18th) -

LC InertSearch Inertsil ODS-4
LB755 - Analysis of Oxaliplatin (Under the Condition of the draft for the Japanese Pharmacopoeia18th supplement II) -

LC InertSearch InertSustainSwift C18
LB754 - Analysis of Saccharin (Under the Condition of the Japanese Pharmacopoeia 18th, Saccharin Sodium Hydrate) -

LC InertSearch Inertsil WP300 C18
LB751 - Analysis ofSulfamethoxazole and Trimethoprim -

LC InertSearch Inertsil WP300 C18
GA342 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 B) -

GC InertSearch InertCap WAX
GA341 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 A) -

GC InertSearch InertCap WAX
GA340 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 1) -

GC InertSearch InertCap WAX
GA339 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 B) -

GC InertSearch InertCap 624MS
GA338 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 A) -

GC InertSearch InertCap 624MS
GA337 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 1) -

GC InertSearch InertCap 624MS
LB699 - Analysis of Refined Glucose (Japanese Pharmacopoeia 18th Edition, Glucose, Assay) -

LC InertSearch InertSphere Sugar-2
LB698 - Analysis of Neomycin Sulfate (European Pharmacopoeia 11.0th Edition, Purity Test) -

LC InertSearch InertSustain C18
GA335 - Analysis of Benzyl Alcohol (Under the condition of the Japanese Pharmacopoeia 18) -

GC InertSearch InertCap Pure-WAX
GA333 - Residual solvents in pharmaceuticals (JP 18 Standard stock solution Class 2 C) -

GC InertSearch InertCap WAX
GA332 - Residual solvents in pharmaceuticals (JP 18 Standard stock solution Class 2 C) -

GC InertSearch InertCap 624MS
GA331 - Residual solvents in pharmaceuticals (JP 18 Standard stock solution Class 2 C) -

GC InertSearch InertCap 624MS
GA330 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 B) -

GC InertSearch InertCap WAX
GA329 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 B) -

GC InertSearch InertCap 624MS
GA328 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 B) -

GC InertSearch InertCap 624MS
GA327 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 A) -

GC InertSearch InertCap WAX
GA326 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 A) -

GC InertSearch InertCap 624MS
GA325 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 2 A) -

GC InertSearch InertCap 624MS
GA324 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 1) -

GC InertSearch InertCap WAX
GA323 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 1) -

GC InertSearch InertCap 624MS
GA322 - Residual solvents in pharmaceuticals (JP18 Standard stock solution Class 1) -

GC InertSearch InertCap 624MS
LB669 - Analysis of Rosuvastatin calcium (Under the condition of the Japanese Pharmacopoeia (JP) ) -

LC InertSearch InertSustainSwift C18
LB660 - Analysis of Copovidone(Under the Condition of European Pharmacopoeia 10.0, Impurity A) -

LC InertSearch Inertsil ODS-4
LB641 - Analysis of Rosuvastatin Calcium (Under the Condition of draft for Japanese Pharmacopoeia, Rosuvastatin Calcium) -

LC InertSearch InertSustain C18
LB640 - Analysis of Rosuvastatin Calcium (Under the Condition of draft for Japanese Pharmacopoeia, Rosuvastatin Calcium) -

LC InertSearch InertSustain C18
LB632 - Analysis of Telmisartan and Amlodipine besilate (Under the Condition of Japanese Pharmacopoeia, Telmisartan and Amlodipine Besilate Tablets) -

LC InertSearch Inertsil C8-3
LB631 - Analysis of Telmisartan and Amlodipine besilate (Under the Condition of Japanese Pharmacopoeia, Telmisartan and Amlodipine Besilate Tablets) -

LC InertSearch Inertsil C8-3
LB630 - Analysis of Amlodipine besilate (Under the Condition of Japanese Pharmacopoeia, Telmisartan and Amlodipine Besilate Tablets) -

LC InertSearch Inertsil C8-3
LB629 - Analysis of Telmisartan (Under the Condition of Japanese Pharmacopoeia, Telmisartan and Amlodipine Besilate Tablets) -

LC InertSearch Inertsil C8-3
LB628 - Analysis of Copovidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (7) 2-Pyrrolidone) -

LC InertSearch Inertsil ODS-3
LB627 - Analysis of Copovidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (4) 1-Vinyl-2-pyrrolidone and vinyl acetate) -

LC InertSearch Inertsil ODS-4
LT147 - D-Mannitol Analysis Under USP Method -

LC Technical Note InertSphere Sugar-2 HAMILTON HC-75（Ca2+）
LT131 - HPLC Columns Compliant with Pharmacopoeia (USP, EP and JP） -

LC Technical Note
LT092 - Analysis of Tranexamic Acid According to the Japanese Pharmacopoeia -

LC Technical Note InertSustain AQ-C18 Inertsil ODS-4
LT080 - Analysis of Sennosides in Senna in Accordance with the Japanese Pharmacopoeia -

LC Technical Note Inertsil ODS-4
LT052 - Analysis of Geniposide with a Photodiode Array Detection -

LC Technical Note Inertsil ODS-SP
LT044 - Analysis of Bufosteroids in Senso In Accordance with the Japanese Pharmacopoeia -

LC Technical Note Inertsil ODS-P
LT040 - Analysis of peony (Chinese paeoniflorin) in accordance with the 15th edition of the Japanese Pharmacopoeia -

LC Technical Note Inertsil ODS-3 Inertsil ODS-SP
LT039 - Analysis of Glycyrrhizic Acid in Licorice According to the Japanese Pharmacopoeia -

LC Technical Note
LT038 - Analysis of Scopolamine and Hyoscyamine in Scopolia Extract in Accordance with the Japanese Pharmacopoeia -

LC Technical Note Inertsil ODS-SP
LB532 - Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets B) -

LC InertSearch InertSustain C18
LB531 - Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets A) -

LC InertSearch InertSustain C18
LB529 - Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc Granules) -

LC InertSearch InertSustain C18
LB528 - Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc) -

LC InertSearch InertSustain C18
LB527 - Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) -

LC InertSearch Inertsil ODS-4
LB526 - Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) -

LC InertSearch Inertsil ODS-4
LB525 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil C8-3
LB524 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia supplement II, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil C8-3
LB523 - Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil C8-3
LB520 - Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustain C18
LB519 - Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustainSwift C18
LB508 - Analysis of Sitagliptin (Under the Condition of the draft for the Japanese Pharmacopoeia, Sitagliptin Phosphate Hydrate) -

LC InertSearch InertSustain Cyano
LB503 - Analysis of Warfarin Potassium (Under the Condition of the Japanese Pharmacopoeia 17th edition, (3) Related subatances) -

LC InertSearch InertSustain Cyano
LB502 - Analysis of Warfarin Potassium (Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch InertSustain Cyano
LB489 - Analysis of Azosemide (Under the Condition of the draft for the Japanese Pharmacopoeia, Azosemide Tablets) -

LC InertSearch InertSustain C18
LB487 - Analysis of Verapamil Hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Verapamil Hydrochloride Tablets) -

LC InertSearch InertSustain C18
LB486 - Analysis of Clomipramine Hydorochloride (Under the Condition of the Japanese Pharmacopoeia, Clomipramine Hydorochloride Tablets) -

LC InertSearch Inertsil ODS-3
LB485 - Analysis of Pyridoxal Phosphate Hydrate (Under the Condition of the Japanese Pharmacopoeia, (4) Related subatances) -

LC InertSearch InertSustain AQ-C18
LB483 - Analysis of Minocycline Hydrochloride (Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch InertSustainSwift C8
LB482 - Analysis of Glycyrrhiza (Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch Inertsil ODS-4
LB477 - Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (7) Formic acid) -

LC InertSearch InertSphere FA-1
LB472 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C8
LB471 - Analysis of Tramadol Hydrochloride (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB453 - Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia, Tranexamic acid Capsules) -

LC InertSearch Inertsil ODS-4
LB452 - Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia, Tranexamic acid Tablets) -

LC InertSearch InertSustain AQ-C18
LB451 - Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain AQ-C18
LB450 - Analysis of Tranexamic acid(Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain AQ-C18
LB449 - Analysis of Lansoprazole(Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB448 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 3-Aminophenol, 3-Aminobenzoic acid, Gentisic acid, Salicylic acid, other related substances and total related substance) -

LC InertSearch InertSustain C8
LB447 - Analysis of Mesalazine(Under the Condition of the draft for the Japanese Pharmacopoeia, (6) 2-Aminophenol and 4-Aminophenol) -

LC InertSearch InertSustainSwift C18 HP
LB446 - Analysis of Hydrocortisone butyrate(Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3 HP
LB445 - Analysis of Pazufloxacin mesilate (Under the Condition of the Japanese Pharmacopoeia 18th edition) -

LC InertSearch Inertsil ODS-3
LB444 - Analysis of Pazufloxacin mesilate(Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-2
LB436 - Analysis of Mesalazine(Under the Condition of the Japanese Pharmacopoeia, (7) Aniline) -

LC InertSearch InertSustain C18
LB435 - Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (6) 2-Pyrrolidone) -

LC InertSearch InertSustain AQ-C18
LB433 - Analysis of Povidone(Under the Condition of the Japanese Pharmacopoeia 17th edition, (4) 1-Vinyl-2-pyrrolidone) -

LC InertSearch InertSustain AQ-C18
LB432 - Analysis of Haloperidol(Under the Condition of the Japanese Pharmacopoeia 17th edition, Haloperidol Tablets) -

LC InertSearch Inertsil ODS-4
LB431 - Analysis of Haloperidol(Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch Inertsil ODS-4
LB430 - Analysis of Tulobuterol Hydrochloride(Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch InertSustain C18
LB429 - Analysis of Tulobuterol(Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch InertSustain C18
LB426 - Analysis of Diflorason Diacetate(Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch InertSustain C18
LB425 - Analysis of Diflorason Diacetate(Under the Condition of the Japanese Pharmacopoeia 17th edition) -

LC InertSearch InertSustain C18
LB424 - Analysis of Eplerenone(Under the Condition of the Japanese Pharmacopoeia 17th edition, Eplerenone Tablets) -

LC InertSearch Inertsil ODS-3
LB420 - Analysis of Acetaminophen (Under the Condition of the Japanese Pharmacopoeia) （InertSustainSwift C18） -

LC InertSearch InertSustainSwift C18
LB419 - Analysis of Acetaminophen (Under the Condition of the Japanese Pharmacopoeia) （InertSustain C18） -

LC InertSearch InertSustain C18
LB415 - Analysis of Methotrexate (Under the Condition of the draft for the Japanese Pharmacopoeia, Methotrexate Tablets) -

LC InertSearch Inertsil ODS-4
LB413 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB412 - Analysis of Eplerenone (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB411 - Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB410 - Analysis of Medroxyprogesterone acetate (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB409 - Analysis of Mesalazine (Under the Condition of the draft for the Japanese Pharmacopoeia, Mesalazine Extended-release Tablets) -

LC InertSearch Inertsil ODS-4
LB408 - Analysis of Fluconazole (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB407 - Analysis of Fluconazole (Under the Condition of the Japanese Pharmacopoeia, Fluconazole Capsules) -

LC InertSearch Inertsil WP300 C18
LB374 - Analysis of Ampiroxicam (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB373 - Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) -

LC InertSearch InertSustainSwift C18
LB372 - Analysis of Cyclophosphamide (Under the Condition of the Japanese Pharmacopoeia, Cyclophosphamide Tablets) -

LC InertSearch InertSustainSwift C18
LB371 - Analysis of Amlodipine besilate (Under the Condition of the Japanese Pharmacopoeia, Amlodipine Besilate Orally Disintegrating Tablets) -

LC InertSearch InertSustainSwift C18
LB370 - Analysis of Prednisolone (Under the Condition of European Pharmacopoeia 8.2) -

LC InertSearch Inertsil ODS-3
LB369 - Analysis of Capsaicin (Under the Condition of the Japanese Pharmacopoeia, Capsicum Tincture) -

LC InertSearch InertSustain Phenyl
LB360 - Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia, Roxithromycin Tablets) -

LC InertSearch InertSustain C18
LB339 - Analysis of Rebamipide (Under the Condition of the Japanese Pharmacopoeia, Rebamipide Tablets) -

LC InertSearch InertSustain C18
LB330 - Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB329 - Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18
LB328 - Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia 16th edition supplement II) -

LC InertSearch InertSustainSwift C18
LB327 - Analysis of Roxithromycin (Under the Condition of the Japanese Pharmacopoeia 16th edition) -

LC InertSearch InertSustainSwift C18
LB310 - Analysis of Voriconazole (Under the Condition of the Japanese Pharmacopoeia, Voriconazole Tablets) -

LC InertSearch Inertsil WP300 C18
LB309 - Analysis of Voriconazole (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB308 - Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil ODS-4
LB307 - Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil ODS-4
LB306 - Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil ODS-4
LB305 - Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil WP300 C18
LB304 - Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil ODS-3
LB303 - Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil ODS-4
LB302 - Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil ODS-4
LB301 - Analysis of Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil ODS-4
LB300 - Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil WP300 C18
LB299 - Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil ODS-3
LB298 - Analysis of Candesartan cilexetil (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB295 - Analysis of Irbesartan (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB291 - Analysis of Ticlopidine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Ticlopidine hydrochloride Tablets) -

LC InertSearch InertSustain C18
LB290 - Analysis of Cefalexin (Under the Condition of the Japanese Pharmacopoeia, Cefalexin Combination Granules) -

LC InertSearch InertSustain C18
LB286 - Analysis of Ribavirin (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4 HP
LB285 - Analysis of Ribavirin (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4 HP
LB284 - Analysis of Silodosin (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB283 - Analysis of Silodosin (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB282 - Analysis of Povidone (Under the Condition of the Japanese Pharmacopoeia 16th edition, (4) 1-Vinyl-2-pyrrolidone) -

LC InertSearch InertSustain C8
LB281 - Analysis of Montelukast sodium (Inertsil Ph) (Under the Condition of the Japanese Pharmacopoeia, Montelukast sodium Tablets) -

LC InertSearch Inertsil Ph
LB279 - Analysis of Indometacin (Under the Condition of European Pharmacopoeia 8.2) -

LC InertSearch InertSustain Phenylhexyl
LB267 - Analysis of D-Mannitol (Under the Condition of the Japanese Pharmacopoeia, D-Mannitol) -

LC InertSearch HC-75(Ca+)
LB265 - Analysis of Tacrolimus (Under the Condition of the Japanese Pharmacopoeia, Tacrolimus Capsules) -

LC InertSearch Inertsil ODS-2
LB264 - Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) -

LC InertSearch Inertsil C8-3
LB262 - Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) -

LC InertSearch InertSustain C8
LB254 - Analysis of Brotizolam (Under the Condition of the Japanese Pharmacopoeia, Brotizolam Tablets) -

LC InertSearch Inertsil WP300 C18
LB253 - Analysis of Tranilast (Under the Condition of the Japanese Pharmacopoeia, Tranilast Capsules) -

LC InertSearch InertSustain C18
LB251 - Analysis of Quetiapine fumarate (Under the Condition of the Japanese Pharmacopoeia, Quetiapine fumarate Tablets) -

LC InertSearch Inertsil C8-4
LB250 - Analysis of Azelnidipine (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB247 - Analysis of Terbinafine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Terbinafine hydrochloride Cream) -

LC InertSearch InertSustainSwift C18
LB246 - Analysis of L-Carbocisteine (Under the Condition of the Japanese Pharmacopoeia, L-Carbocisteine Tablets) -

LC InertSearch Inertsil ODS-4
LB245 - Analysis of L-Carbocisteine (Under the Condition of the Japanese Pharmacopoeia, L-Carbocisteine Tablets) -

LC InertSearch Inertsil ODS-4
LB243 - Analysis of Acarbose (Under the Condition of the Japanese Pharmacopoeia, Acarbose Tablets) -

LC InertSearch Inertsil WP300 C18
LB232 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18 HP
LB231 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18 HP
LB230 - Analysis of Leuprorelin acetate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustainSwift C18 HP
LB223 - Analysis of Cilnidipine (Under the Condition of the Japanese Pharmacopoeia, Cilnidipine Tablets) -

LC InertSearch Inertsil ODS-4
LB222 - Analysis of Butenafine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18 HP
LB210 - Analysis of Pioglitazone hydrochloride (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB209 - Analysis of Pioglitazone hydrochloride (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB205 - Analysis of Paroxetine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Paroxetine hydrochloride Tablets) -

LC InertSearch Inertsil TMS
LB204 - Analysis of Metformin hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C18
LB203 - Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil Tablets) -

LC InertSearch Inertsil ODS-3
LB202 - Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil Tablets) -

LC InertSearch Inertsil ODS-3
LB201 - Analysis of Candesartan cilexetil (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LB196 - Analysis of Ciprofloxacin hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Ciprofloxacin hydrochloride hydrate) -

LC InertSearch InertSustain C18
LB195 - Analysis of Metformin hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB194 - Analysis of Metformin hydrochloride (Inertsil C8-3) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch Inertsil C8-3
LB193 - Analysis of Pioglitazone hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB192 - Analysis of Pioglitazone hydrochloride (Inertsil C8-3) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch Inertsil C8-3
LB191 - Analysis of Metformin hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB190 - Analysis of Metformin hydrochloride (Inertsil C8-3) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch Inertsil C8-3
LB189 - Analysis of Pioglitazone hydrochloride (InertSustain C8) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB188 - Analysis of Pioglitazone hydrochloride (Inertsil C8-3) (Under the Condition of the Japanese Pharmacopoeia, Pioglitazone hydrochloride and Metformin hydrochloride Tablets) -

LC InertSearch Inertsil C8-3
LB187 - Analysis of Chlorpheniramine maleate (Under the Condition of the Japanese Pharmacopoeia,Chlorpheniramine maleate Tablets) -

LC InertSearch InertSustain C18
LB186 - Analysis of Chlorpheniramine maleate (Under the Condition of the Japanese Pharmacopoeia,Chlorpheniramine maleate Tablets) -

LC InertSearch InertSustain C18
LB185 - Analysis of Chlorpheniramine maleate (Under the Condition of the Japanese Pharmacopoeia,Chlorpheniramine maleate Tablets) -

LC InertSearch InertSustain C18
LB184 - Analysis of Phellodendron Bark (Inertsil ODS-3) (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LB183 - Analysis of Phellodendron Bark (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB182 - Analysis of Glycyrrhiza (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB181 - Analysis of Glycyrrhiza (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB177 - Analysis of Povidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (8) 2-pyrrolidone) -

LC InertSearch InertSustain C18
LB176 - Analysis of Povidone (Under the Condition of the draft for the Japanese Pharmacopoeia, (4) 1-Vinyl-2-pyrrolidone) -

LC InertSearch InertSustain C18
LB175 - Analysis of Loxoprofen (Under the Condition of the Japanese Pharmacopoeia, Loxoprofen sodium Tablets) -

LC InertSearch InertSustain C18
LB174 - Analysis of d-Chlorpheniramine maleate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LB173 - Analysis of Azelastine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB167 - Analysis of Crospovidone (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB166 - Analysis of Pravastatin Sodium (Under the Condition of the Japanese Pharmacopoeia,Pravastatin Sodium Tablets) -

LC InertSearch Inertsil WP300 C18
LB165 - Analysis of Pravastatin Sodium (Under the Condition of the Japanese Pharmacopoeia, Pravastatin Sodium Tablets) -

LC InertSearch Inertsil ODS-4
LB164 - Analysis of Telmisartan (Under the Condition of the Japanese Pharmacopoeia, Telmisartan Tablets) -

LC InertSearch Inertsil ODS-4
LB163 - Analysis of Telmisartan (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-SP
LB162 - Analysis of Clopidogrel sulfate (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia, Clopidogrel sulfate Tablets) -

LC InertSearch Inertsil WP300 C18
LB160 - Analysis of Clopidogrel sulfate (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB159 - Analysis of Clopidogrel sulfate (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB158 - Analysis of Clopidogrel sulfate (Inertsil WP300 C18) (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB157 - Analysis of Clopidogrel sulfate (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB156 - Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Amlodipine besylate Tablets) -

LC InertSearch Inertsil ODS-4
LB155 - Analysis of Amlodipine besylate (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Amlodipine besylate Tablets) -

LC InertSearch Inertsil ODS-4
LB154 - Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Amlodipine besylate Tablets) -

LC InertSearch Inertsil ODS-4
LB153 - Analysis of Candesartan cilexetil (Under the Condition of the Japanese Pharmacopoeia, Candesartan cilexetil and Amlodipine besylate Tablets) -

LC InertSearch Inertsil ODS-SP
LB152 - Analysis of Epinastine hydrochloride (Under the Condition of the Japanese Pharmacopoeia, Epinastine Hydrochloride Tablets) -

LC InertSearch Inertsil C8-4
LB148 - Analysis of Cyanocobalamin (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB134 - Analysis of Fexofenadine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil Ph
LB133 - Analysis of Fexofenadine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil Ph
LB128 - Analysis of Teprenone (Under the Condition of the Japanese Pharmacopoeia, Teprenone Capsules) -

LC InertSearch Inertsil ODS-2
LB127 - Analysis of Etizolam (Under the Condition of the Japanese Pharmacopoeia, Etizolam Tablets) -

LC InertSearch Inertsil ODS-3
LB126 - Analysis of Risperidone (Under the Condition of the Japanese Pharmacopoeia, Risperidone Tablets) -

LC InertSearch Inertsil WP300 C18
LB125 - Analysis of Risperidone (Under the Condition of the Japanese Pharmacopoeia, Risperidone Tablets) -

LC InertSearch Inertsil WP300 C18
LB124 - Analysis of Ipriflavone (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB123 - Analysis of Ipriflavone (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB122 - Analysis of Simvastatin (Under the Condition of the Japanese Pharmacopoeia, Simvastatin Tablets) -

LC InertSearch Inertsil WP300 C18
LB121 - Analysis of Simvastatin (Under the Condition of the Japanese Pharmacopoeia, Simvastatin Tablets) -

LC InertSearch Inertsil WP300 C18
LB120 - Analysis of Simvastatin (Under the Condition of the Japanese Pharmacopoeia, Simvastatin Tablets) -

LC InertSearch Inertsil WP300 C18
LB119 - Analysis of Glimepiride (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LB118 - Analysis of Glimepiride (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LB117 - Analysis of Mecobalamin (Under the Condition of the Japanese Pharmacopoeia, Mecobalamin Tablets) -

LC InertSearch Inertsil ODS-4
LB116 - Analysis of Mecobalamin (Under the Condition of the Japanese Pharmacopoeia, Mecobalamin Tablets) -

LC InertSearch Inertsil ODS-4
LB115 - Analysis of Mecobalamin (Under the Condition of the Japanese Pharmacopoeia, Mecobalamin Tablets) -

LC InertSearch Inertsil ODS-4
LB114 - Analysis of Epalrestat (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB113 - Analysis of Epalrestat (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB112 - Analysis of Sivelestat sodium hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB111 - Analysis of Sivelestat sodium hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB106 - Analysis of Pitavastatin calcium tablets (Under the Condition of the draft for the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB104 - Analysis of Pitavastatin calcium (Under the Condition of the Japanese Pharmacopoeia, Pitavastatin calcium hydrate) -

LC InertSearch Inertsil ODS-4
LB103 - Analysis of Pilsicainide hydrochloride hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB102 - Analysis of Donepezil hydrochloride (Under the Condition of Japanese Pharmacopoeia, Donepezil hydrochloride tablets) -

LC InertSearch Inertsil ODS-2
LB101 - Analysis of Brotizolam (Under the Condition of the Japanese Pharmacopoeia, Brotizolam tablets) -

LC InertSearch Inertsil WP300 C18
LB100 - Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB098 - Analysis of p-Hydroxybenzoic acid n-propyl ester (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB097 - Analysis of p-Hydroxybenzoic acid ethyl ester (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB096 - Analysis of p-Hydroxybenzoic acid methyl ester (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB095 - Analysis of Edaravone Injection (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LB093 - Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB092 - Analysis of Edaravone (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LB087 - Analysis of Naftopidil (Under the Condition of the Japanese Pharmacopoeia, Naftopidil Tablets) -

LC InertSearch InertSustain C18
LB086 - Analysis of Naftopidil (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB083 - Analysis of Ranitidine hydrochloride (Under the Condition of Japanese Pharmacopoeia 16) -

LC InertSearch ODS
LB082 - Analysis of Sertraline hydrochloride (Under the Condition of European Pharmacopoeia 7.0) -

LC InertSearch Inertsil ODS-3
LB066 - Analysis of Mosapride Citrate Tablets (Under the Condition of Japanese Pharmacopoeia 16) -

LC InertSearch InertSustain C18
LB065 - Analysis of Brotizolam(Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C8
LB064 - Analysis of Tranilast (Inertsil ODS-4)(Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB063 - Analysis of Tranilast (InertSustain C18)(Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB062 - Analysis of Cetiridine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Cetiridine hydrochloride Tablets) -

LC InertSearch Inertsil C8-3
LB061 - Analysis of Sarpogrelate Hydrochloride (Under the Condition of Japanese Pharmacopoeia 16) -

LC InertSearch Inertsil ODS-2
LB060 - Analysis of Quetiapine Fumarate (Under the Condition of the Japanese Pharmacopoeia, Quetiapine Fumarate Tablets) -

LC InertSearch Inertsil C8-4
LB059 - Analysis of Quetiapine Fumarate (Under the Condition of the Japanese Pharmacopoeia) -

LC InertSearch Inertsil C8-4
LB058 - Analysis of Amlodipine Besilate (Under the Condition of Japanese Pharmacopoeia, Amlodipine Besilate Tablets) -

LC InertSearch InertSustain C18
LB057 - Analysis of Acetylcysteine (Under the Condition of Japanese Pharmacopoeia 16) -

LC InertSearch Inertsil ODS-4
LB056 - Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB055 - Analysis of Olopatadine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) -

LC InertSearch InertSustain C8
LB054 - Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch InertSustain C8
LB037 - Analysis of Terbinafine HCl (Inertsil ODS-4) (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-4
LB036 - Analysis of Terbinafine HCl (Inertsil ODS-3) (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LB035 - Analysis of Terbinafine HCl (InertSustain C18) (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LB025 - Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Hydrate) -

LC InertSearch InertSustain C18
LB024 - Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Tablets) -

LC InertSearch InertSustain C18
LB023 - Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Tablets) -

LC InertSearch InertSustain C18
LB017 - Analysis of Furosemide(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LA972 - Analysis of Loxoprofen- InertSustain C18(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch InertSustain C18
LA971 - Analysis of Loxoprofen- Inertsil ODS-SP(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-SP
LA970 - Analysis of Salicylic acid(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-P
LA941 - Analysis of Terbinafine Chloride cream(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LA940 - Analysis of Terbinafine Chloride(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil WP300 C18
LA900 - Analysis of Lincomycin(Under the Condition of Japanese Pharmacopoeia 16) -

LC InertSearch Inertsil C8-4
LA899 - Analysis of Rifampicin(Under the Condition of Japanese Pharmacopoeia 16) -

LC InertSearch Inertsil C8-4
LA664 - Analysis of Clindamycin Phosphate (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil C8-4
LA663 - Analysis of Clindamycin Phosphate (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil C8-3
LA573 - Analysis of Scopolia Extract (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-SP
LA558 - Analysis of Scopolia Standard (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-SP
LA556 - Analysis of Toad Venom Extract (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-P
LA555 - Analysis of Toad Venom Extract (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-P
LA554 - Analysis of Voglibose by Post - Column HPLC (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch
LA553 - Analysis of Paeoniae radix extract(Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LA552 - Analysis of Paeoniae Standard (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-3
LA551 - Analysis of Glycyrrhiza Extract (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-SP
LA550 - Analysis of Glycyrrhiza Standard (Under the Condition of Japanese Pharmacopoeia) -

LC InertSearch Inertsil ODS-SP
GT093 - Quantitative Test for Hydroxypropylcellulose with Reference to the Japanese Pharmacopoeia, 17th Edition -

GC Technical Note InertCap 1 InertCap Series
GT087 - Purity Test of Olive Oil, with reference to the Japanese Pharmacopoeia, 16th Edition -Comparisons of Chromosorb Series and Uniport Series of Siliceous Soil Supports -

GC Technical Note
GT086 - Purity Test and Fatty Acid Content Ratio Test of Polysorbate 80 - Supplement II to the Japanese Pharmacopoeia, 16th Edition -

GC Technical Note InertCap Pure-WAX InertCap 5
GT085 - Water Testing of Panipenem - with Reference to the Japanese Pharmacopoeia 16th Edition -

GC Technical Note
GT083 - Purity Test of Calcium Polystyrene Sulfonate, with reference to the Japanese Pharmacopoeia, 16th Edition - Comparisons of Chromosorb Series and Uniport Series of Siliceous Soil Support -

GC Technical Note
GT056 - Purity Test of Colchicine with Reference to the Japanese Pharmacopoeia -

GC Technical Note InertCap Pure-WAX
GT054 - Purity Test of Epirubicin Hydrochloride with Reference to the Japanese Pharmacopoeia -

GC Technical Note InertCap WAX
GT034 - Purity Test of Benzyl Alcohol with Reference to the Japanese Pharmacopoeia -

GC Technical Note InertCap Pure-WAX
GA281 - Residual solvents in pharmaceuticals -

GC InertSearch InertCap WAX
GA275 - Analysis of Hydroxypropyl Cellulose(Under the Condition of the draft for the Japanese Pharmacopoeia) -

GC InertSearch InertCap 1
GA274 - Analysis of Tulobuterol Transdermal Tapes(Under the Condition of the draft for the Japanese Pharmacopoeia) -

GC InertSearch InertCap 1
GA269 - 2-Pyrrolidone -

GC InertSearch InertCap Pure-WAX
GA268 - Analysis of Sevoflurane(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 624
GA267 - Analysis of Sevoflurane(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 624
GA266 - Analysis of Sevoflurane(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 624
GA265 - Propylene glycol(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 1701
GA264 - Propylene glycol(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 1701
GA263 - Glycerin, Concentrated glycerin(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 1701
GA262 - Glycerin, Concentrated glycerin(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 1701
GA251 - Analysis of Stearic Acid(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap Pure-WAX
GA248 - Analysis of Iohexol(Under the Condition of the Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 5
GA247 - Analysis of Iohexol(Under the Condition of the Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 5
GA246 - Analysis of Bupivacaine hydrochloride hydrate(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 5
GA245 - Analysis of Sertraline Hydrochloride(Under the Condition of European Pharmacopoeia 7.0) -

GC InertSearch InertCap 17
GA244 - Analysis of Clomifene Citrate(Under the Condition of Japanese Pharmacopoeia 16) -

GC InertSearch InertCap 1 Custom-made
GA210 - Propylene glycol,Diethylene glycol,Ethylene glycol -

GC InertSearch InertCap 1701
GA209 - Glycerin,Diethylene glycol,Ethylene glycol -

GC InertSearch InertCap 1701
GA203 - Organic solvents -

GC InertSearch TC-BOND U
GA202 - Organic solvents -

GC InertSearch TC-BOND Q
GA167 - Purity test of Benzyl alcohol by Japanese pharmacopoeia -

GC InertSearch InertCap WAX
GA166 - Purity test of Epirubicin Hydrochloride by Japanese pharmacopoeia -

GC InertSearch InertCap Pure-WAX
GA165 - Purity test of Magnesium stearate by Japanese pharmacopoeia -

GC InertSearch InertCap WAX
GA164 - Purity test of Magnesium stearate by Japanese pharmacopoeia -

GC InertSearch InertCap Pure-WAX
GA155 - Purity test of Colchicine by Japanese pharmacopoeia -

GC InertSearch InertCap Pure-WAX
GA154 - Purity test of Wood Creosote by Japanese pharmacopoeia -

GC InertSearch InertCap 1
GA151 - Purity test of Acethexamide -

GC InertSearch InertCap 1
GA145 - Purity test of Colchicine -

GC InertSearch InertCap WAX
GA144 - Purity test of Epirubicin Hydrochloride -

GC InertSearch InertCap WAX
GA134 - Higher Alcohols -

GC InertSearch InertCap 5
GA128 - Residual solvents in pharmaceuticals -

GC InertSearch InertCap 5
GA127 - Residual solvents in pharmaceuticals Class3 -

GC InertSearch InertCap 5
GA126 - Residual solvents in pharmaceuticals Class2 -

GC InertSearch InertCap 5
GA125 - Residual solvents in pharmaceuticals Class1 -

GC InertSearch InertCap 5
GA124 - Residual solvents in pharmaceuticals -

GC InertSearch InertCap 5
GA123 - Residual solvents in pharmaceuticals -

GC InertSearch InertCap 624
GA100 - Glycol ＆ Glycerine -

GC InertSearch InertCap 1701
GA099 - Glycol ＆ Glycerine -

GC InertSearch InertCap 1
GA097 - Organic solvents -

GC InertSearch InertCap Pure-WAX
GA096 - Organic solvents -

GC InertSearch InertCap 624
GA094 - Residual solvents in pharmaceuticals Class3 -

GC InertSearch InertCap Pure-WAX
GA093 - Residual solvents in pharmaceuticals Class3 -

GC InertSearch InertCap 624
GA092 - Residual solvents in pharmaceuticals Class2 -

GC InertSearch InertCap Pure-WAX
GA091 - Residual solvents in pharmaceuticals Class2 -

GC InertSearch InertCap 624
GA090 - Residual solvents in pharmaceuticals Class1 -

GC InertSearch InertCap Pure-WAX
GA089 - Residual solvents in pharmaceuticals Class1 -

GC InertSearch InertCap 624
GA087 - Organic solvents -

GC InertSearch InertCap Pure-WAX
GA086 - Organic solvents -

GC InertSearch InertCap Pure-WAX
GA084 - Organic solvents -

GC InertSearch InertCap Pure-WAX
GA079 - Organic solvents -

GC InertSearch InertCap Pure-WAX
GA078 - Organic solvents -

GC InertSearch InertCap Pure-WAX
GA071 - Glycerin, Diethylene glycol -

GC InertSearch InertCap 1701
GA037 - Organic solvents -

GC InertSearch InertCap WAX
GA036 - Organic solvents -

GC InertSearch InertCap 5
GA035 - Organic solvents -

GC InertSearch InertCap 1701
GA034 - Organic solvents -

GC InertSearch InertCap 17
GA033 - Organic solvents -

GC InertSearch InertCap 1
GA028 - Organic solvents -

GC InertSearch InertCap 25
GA027 - Organic solvents -

GC InertSearch InertCap 5MS/Sil
GA026 - Organic solvents -

GC InertSearch InertCap AQUATIC-2
GA023 - Organic solvents -

GC InertSearch InertCap WAX
GA012 - Organic solvents -

GC InertSearch InertCap 1

Applications including "Pharmacopoeia"

LT199 - Analysis of voglibose tablets in accordance with the 18th revised Japanese Pharmacopoeia -

LT195 - Eighteenth revision Japanese Pharmacopoeia analysis of tranexamic acid -2.00 Condition change within the range specified in the general chromatography- -

GT146 - Japanese Pharmacopoeia, 18th Edition Analysis of Saccharin Sodium Hydrate - 2.00 Change of Conditions Specified within General Theory of Chromatography -

GT145 - Japanese Pharmacopoeia, 18th Edition Analysis of Macrogol 400 - 2.00 Change of Conditions Specified within General Theory of Chromatography -

LB263 - Analysis of Losartan Potassium and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia, Losartan Potassium and Hydrochlorothiazide Tablets) -

LB206 - Analysis of Paroxetine hydrochloride (Under the Condition of the Japanese Pharmacopoeia) -

LB161 - Analysis of Clopidogrel sulfate (InertSustain C18) (Under the Condition of the Japanese Pharmacopoeia, Clopidogrel sulfate Tablets) -

LB099 - Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) -

LB094 - Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) -

LB085 - Analysis of Olmesartan medoxomil (Under the Condition of the Japanese Pharmacopoeia) -

GA271 - Analysis of Polysorbate80(Under the Condition of Japanese Pharmacopoeia 16) -

GA270 - Analysis of Polysorbate80(Under the Condition of Japanese Pharmacopoeia 16) -

GA113 - Residual solvents in pharmaceuticals -

GA029 - Organic solvents -

GA397 - Analysis of Nitromethane(Under the Condition of draft for USP, Tromethamine Hydrochloride, Limit of Nitromethane) -

LC110 - Analysis of Quinic acid, Malic acid, Citric acid, Shikimic acid (Under the Condition of draft for USP, Aronia melanocarpa Fruit Aqueous Dry Extract, IDENTIFICATION C.HPLC PROFILE AND RATIO OF ORGANIC ACIDS) -

LC109 - Analysis of Prazosin hydrochloride (Under the Condition of draft for USP, Prazosin Hydrochloride Compounded Oral Suspension, ASSAY) -

LC108 - Analysis of Formoterol fumarate (Under the Condition of draft for USP, Formoterol Fumarate Inhalation Solution, Assay) -

LC105 - Analysis of Cefalexin (Under the Condition of Japanese Pharmacopoeia 18th, Cefalexin,Purity(3) Related substances ) -

LC100 - Analysis of Omeprazole(Under the Condition of USP41-NF36, Omeprazole Delayed-Release Capsules, ASSAY) -

LL043 - Analysis of Azithromycin (Based on the Condition of USP-NF 2025 Issue 2 Mar, Azithromycin Tablets, ORGANIC IMPURITIES) -

LC099 - Analysis of Ascorbic acid (Under the Condition of draft for USP, Water-Soluble Vitamins Chewable Gels, Ascorbic acid, Method 1) -

LC098 - Analysis of Tramadol Hydrochloride (Under the Condition of draft for USP, Tramadol Hydrochloride Tablets, ASSAY) -

LC096 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ORGANIC IMPURITIES) -

LC095 - Analysis of Adapalene (Under the Condition of draft for USP, Adapalene Cream,ASSAY) -

LC072 - Analysis of Vitamin K１ (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PHYTONADIONE) -

LC070 - Analysis of Vitamin A (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin A,Method 1) -

LC068 - Analysis of Gliclazide (Under the Condition of the draft for Japanese Pharmacopoeia, Gliclazide Tablets, ASSAY) -

LC067 - Analysis of Rebamipide (Under the Condition of the Japanese Pharmacopoeia 18th, Rebamipide, Purity (4) Related Substances -

LC066 - Analysis of Cidofovir (Under the Condition of USP43-NF38, Cidofovir, ASSAY) -

LC065 - Analysis of Vitamin E (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 1) -

LC064 - Analysis of Pioglitazone Hydrochloride and Glimepiride (Under the Condition of the Japanese Pharmacopoeia 18th, Pioglitazone Hydrochloride and Glimepiride Tablets, ASSAY(2)Glimepiride) -

LC063 - Analysis of Pioglitazone Hydrochloride and Glimepiride (Under the Condition of the Japanese Pharmacopoeia 18th, Pioglitazone Hydrochloride and Glimepiride Tablets, ASSAY(1)Pioglitazone Hydrochloride) -

LC062 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin, DISSOLUTION) -

LC061 - Analysis of Azithromycin (Under the Condition of USP NF 2025 Issue 2 Mar, Azithromycin,ASSAY) -

LC060 - Analysis of Aspirin (Under the Condition of the draft for the Japanese Pharmacopoeia 19th, Aspirin Delayed-release Tablets, ASSAY) -

LC059 - Analysis of 1-Fluoro-2,4-dinitrophenyl-5-L-alaninamide (Under the Condition of the draft for the Japanese Pharmacopoeia 19th, Pregabalin, 1-Fluoro-2,4-dinitrophenyl-5-L-alaninamide, Assay) -

LC058 - Analysis of Folic acid (Under the Condition of USP NF 2022 ISSUE 3, <411>FOLIC ACID ASSAY,_Procedure 1) -

LC057 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Tablets, ASSAY) -

LC056 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol, ASSAY) -

LC055 - Analysis of Dobutamine (Under the Condition of the USPNF 2023 Issue 2, Dobutamine Hydrochloride, ASSAY) -

LC054 - Analysis of Methocarbamol (Under the Condition of USP43-NF38, Methocarbamol Injection, ASSAY) -

LC053 - Analysis of Folic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,FOLIC ACID_Method 2) -

LC052 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 2) -

LC051 - Analysis of Vitamin C (Under the Condition of USP41-NF36, Vitamin C ASSAY,PROCEDURE 1) -

LC050 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 3) -

LC049 - Analysis of Vitamin E (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Vitamin E_Method 2) -

LC042 - Analysis of Nicotinic acid,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method3 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method3) -

LC041 - Analysis of Nicotinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method1 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method1) -

LC040 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, IMPURITIES, Limit of Free 4-Aminophenol) -

LC039 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, ASSAY) -

LC037 - Analysis of Amlodipine Besilate (Under the Condition of the Japanese Pharmacopoeia 18th, Amlodipine Besilate, Purity(2) Related Substances) -

LC036 - Analysis of Zonisamide (Under the Condition of USP41-NF36, Zonisamide Compounded Oral Suspension, ASSAY) -

LC035 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide Capsules, ASSAY) -

LC034 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide, ASSAY) -

LC033 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Oil- and Water-Soluble Vitamins Minerals Tablets,BIOTIN_Method 3) -

LC032 - Analysis of D‐Biotin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,BIOTIN_Method 1) -

LC031 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Biotin) -

LC029 - Analysis of Riboflavin (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,RIBOFLAVIN_Method 2) -

LC028 - Analysis of Pyridoxine hydrochloride (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PYRIDOXINE HYDROCHLORIDE_Method 2) -

LC027 - Analysis of Nicotinamide (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,NIACINAMIDE_Method 2) -

LC026 - Analysis of Nicotinic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin_Method 2) -

LC023 - Analysis of Lansoprazole (Under the Condition of the USP41-NF36, Lansoprazole Compounded Oral Suspension, ASSAY) -

LC022 - Analysis of Ursodeoxycholic acid (Under the Condition of the Japanese Pharmacopoeia 18th, Ursodeoxycholic acid Tablets, Ursodeoxycholic acid Granules) -

LC021 - Analysis of Cyanocobalamin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Cyanocobalamin_Method1) -

LC017 - Analysis of Itraconazole (Under the Condition of Japanese Pharmacopoeia 18th, Itraconazole, Purity(2) Related substances) -

LC016 - Analysis of Itraconazole (Under the Condition of USP-NF 2021 Issue 2, Itraconazole Capsules, ASSAY) -

LC014 - Analysis of Itraconazole (Under the Condition of USP43-NF38, Itraconazole, ASSAY) -

LC012 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

LC009 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC008 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LB991 - Analysis of Progestrone and Methyltestrone -

LB985 - Analysis of Sumatriptan -

LB984 - Analysis of Sumatriptan -

LB982 - Analysis of Ofloxacin -

LB981 - Analysis of Ofloxacin -

LB980 - Analysis of Desloratadine -

LB978 - Analysis of Hydrochlorothiazide -

LB961 - Analysis of Lidocaine -